Schering-Plough selects metabolic compound for development

Schering-Plough has selected a compound identified in its ongoing collaboration with Pharmacopeia for preclinical development. The compound will be examined as a potential treatment for metabolic diseases, the companies said this week. According to the firms’ collaboration agreement, Schering-Plough is responsible for further development of the compounds. Pharmacopeia is eligible to receive milestone payments if the program advances into late-stage clinical trials and future royalties on sales of resulting products. Pharmacopeia and Schering-Plough have been collaborating on the discovery of novel compounds, for further research and development by Schering-Plough, since 1994. This latest compound is the collaboration’s sixth drug candidate currently in development. Presently, Schering-Plough is investigating a CXCR- 2 antagonist from the collaboration as a potential treatment for chronic obstructive pulmonary disease (COPD) in Phase I clinical trials.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.